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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of pramlintide for diabetes mellitus.
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B A C K G R O U N D
Description of the condition
The World Health Organisation defines diabetes mellitus as a
metabolic disorder characterised by chronic hyperglycaemia with
disturbances of carbohydrate, fat, and protein metabolism result-
ing from defects in insulin secretion, insulin action or both. The
effects of diabetes mellitus include long-term damage, dysfunction
and failure of various organs (WHO 1998).
Of the major aetiological forms of diabetes mellitus, type 1 and
type 2 diabetes account for the majority of cases. In both type 1
and type 2 diabetes there is a decline in the secretory function
of pancreatic beta-cells. In type 1 diabetes the decline in insulin
secretion to an absolute deficit of insulin is usually rapid and it
is due to an autoimmune process or, less frequently, to unknown,
idiopathic destruction of pancreatic beta-cells. In type 2 diabetes
mellitus two processes coexist and interact over the course of the
disease: insulin resistance - that is a diminished effect of insulin -
and insulin deficiency (Kahn 2003). Insulin resistance in type 2
diabetes is frequently related to overweight and obesity. In type 2
diabetes insulin secretion failure is usually slow compared to type
1 diabetes with a progressive loss of beta-cells function and beta-
cells mass due to yet unknown causes, other than autoimmunity
but eventually determining the need for exogenous insulin admin-
istration to correct chronic hyperglycaemia (Weir 2004).
Since the discovery of insulin made survival in diabetes possible
accumulating epidemiological evidence demonstrated the causal
relationship between hyperglycaemia and diabetes specific com-
plications like retinopathy with the potential evolution to blind-
ness, nephropathy potentially leading to end-stage renal failure and
neuropathy. The effect of treating hyperglycaemia in preventing
the development and progression of diabetes complications was
convincingly demonstrated by two landmark trials - the DCCT in
type 1 diabetes (DCCT 1993) and the UKPDS in type 2 diabetes
(UKPDS 1998)
Cardiovascular disease due to premature and extensive atheroscle-
rosis is increased in both type 1 and type 2 diabetes. Intensive
treatment of hyperglycaemia was demonstrated to have a bene-
ficial long term effect on cardiovascular morbidity and mortal-
ity in type 1 diabetes (DCCT/EDIC 2005). Major cardiovascular
events as sudden death, myocardial infarction, stroke are the most
important causes of death among type 2 diabetic patients. Treat-
ing hyperglycaemia in type 2 diabetes decreases cardiovascular risk
(UKPDS 1998; UKPDS-80 2008). Nevertheless, the current out-
look of the medical community on treatment in type 2 diabetes is
a multifactorial, integrated approach with an early and intensive
control of all the contributing cardiovascular risk factors of which
hyperglycaemia is one factor (Gaede 2004). Of these factors, hy-
perglycaemia appears to be the most difficult to control . Recently
published results from three large randomised clinical trials have
drawn attention upon: the potential risk associated with treatment
induced hypoglycaemia and, possibly, other safety aspects of mul-
tiple associated therapies in type 2 diabetes (ACCORD 2008) the
beneficial effect and relative safety of early interventions on gly-
caemic control in the development ofmicrovascular complications
such as nephropathy andonmacrovascular outcomes (ADVANCE
2008; ADVANCE 2009) as compared to the ineffectiveness of late
intervention on glycaemic control in the progression of cardiovas-
cular disease (VADT 2009).
For a detailed overview of diabetes mellitus, please see under
’ Additional information’ in the information on the Metabolic
and Endocrine Disorders Group in The Cochrane Library ( see
’About’, ’Cochrane Review Groups (CRGs)’).For an explanation
of methodological terms, see the main glossary in The Cochrane
Library.
Description of the intervention
The importance of treating postprandial
hyperglycaemia in diabetes mellitus
Diabetes related complications develop overmany years or decades
from diagnosis. Therefore, glycosylated haemoglobin (HbA1c) is
used as a predictive measurement for developing diabetes related
complications as well as a measurement of drugs’ effect - evalu-
ative instrument - in treating hyperglycaemia in clinical practice
(ADA 2008). A widespread use of HbA1c changes with treat-
ment is that of a ’surrogate endpoint ’ in diabetes-drugs approval
trials (Bucher 2008). Glycosylated haemoglobin is a composite
measurement incorporating information on fasting, inter-prandial
glycaemic values and post-prandial glycaemic excursions. Due to
deficient insulin secretion or a combination of inadequate insulin
secretion and an altered insulin action in diabetes, post-prandial
glycaemic increases are of higher amplitude and last much longer
compared to non-diabetic persons, making a larger contribution
to the overall glycaemic control as expressed by Hb A1c (Monnier
2006;Monnier 2009). Recent experimental work and expert opin-
ion suggest a possible independent role for postprandial hyper-
glycaemia in the development of late complications in diabetes
(Cerriello 2005).
In type 1 diabetes glycaemic control can be achieved by insulin
administration either as multiple daily injections or by continu-
ous subcutaneous insulin infusion (CSII), with short or rapid act-
ing insulin delivered at meals or by increasing the rate of insulin
infusion as to prevent postprandial glycaemic raises. Pramlintide
addition to mealtime insulin may be another choice in treating
postprandial hyperglycaemia in type 1 diabetes.
In type 2 diabetes there is a wide armamentarium of antidia-
betic drugs to decrease glycaemic values, with new drugs and new
classes of drugs reaching the market continuously (Nathan 2007;
Nathan 2009). Some classes of drugs target specifically postpran-
dial hyperglycaemia: alfa-glucosidase inhibitors such as acarbose
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and miglitol, meglitinides such as repaglinide and nateglinide. Of
the traditional classes of antidiabetic drugs, both sulphonylurea
and metformin exert lowering effects on postprandial glycaemic
values. Exenatide - the first approved compound of a new class
of drugs - the GLP-1 agonists- appears to lower more efficiently
postprandial glycaemia than fasting glycaemia. The effect of these
agents depends largely on the stage of beta-cell dysfunction in type
2 diabetes. In some patients with type 2 diabetes postprandial glu-
cose control can be achieved only by prandial insulin administra-
tion, either premixed with longer acting insulins or as short or
rapid-acting insulin administered before meals. Pramlintide has
also been approved for use as adjunct therapy to mealtime insulin
in type 2 diabetes. Therapies aiming at lowering postprandial gly-
caemia - such as sulphonylurea, prandial insulin and meglitinides
- also induce variable weight increase. This effect is not observed
with α-glucosidase inhibitors, metformin, exenatide and pramlin-
tide, these drugs appear to induce a variable weight reduction. As
the majority of type 2 diabetic patients are overweight and obese,
weight gain with therapy in type 2 diabetes is undesirable and may
be deleterious .
How the intervention might work
Pramlintide was approved for use by the U.S. FDA in 2005, as
an adjunct therapy to mealtime insulin, aimed at decreasing post-
prandial glucose values in patients with type 1 and type 2 diabetes
mellitus that can not achieve the desired glycaemic goals with in-
sulin only (U.S. FDA 2009).
Pramlintide was developed following the discovery in 1987 of
amylin, a polypeptide co-produced and co-secreted with insulin
by the beta -cells of the pancreas. Amylin has been demonstrated
to produce additional effects to insulin in lowering plasma glu-
cose. Synthesis and secretion of amylin parallel that of insulin and
amylin is deficient in diabetes.
As native amylin is unstable and has a tendency to aggregate and
formmacromolecules, a synthetic, stable derivative was developed
as pramlintide acetate. Early clinical studies have demonstrated the
pharmacological effects of pramlintide that determine the drug’s
beneficial role in decreasing postprandial glucose values: delayed
gastric emptying determining a slower appearance of nutrients in
plasma (Kong 1997; Thompson 1997) increasing satiety partly
due to delayed gastric emptying; inhibition of excessive glucagon
secretion possibly by a direct effect on the alfa-cells of the pancreas
( Fineman 2002; Nyholm 1999). More recently, a possible central
neural effect of pramlintide on specific amylin receptors with po-
tential therapeutic applications was conceptualised (Roth 2009).
Randomised clinical trials have further confirmed the beneficial
effects of pramlintide in both type 1 and type 2 diabetes as well as
the potential adverse effects of the drug. A decrease in postpran-
dial glucose levels and a decrease in HbA1c levels accompanied
by weight loss was reported in both type 1 and type 2 diabetic
patients treated with pramlintide.
Pramlintide is administered prior to meals, by subcutaneous in-
jections. In type 1 diabetes, recommended doses are 15 mcg per
dose to 60 mcg per dose, with a stepwise increase starting with the
lowest dose of 15 mcg. In type 2 diabetes, recommended doses
are 60 mcg per dose to 120 mcg per dose following the same step-
wise increase of dosage. Adjustments of insulin dose at meals are
recommended with possible decreases if needed especially in the
beginning of the treatment.
Adverse effects of the intervention
In clinical trials the most frequently reported adverse events were
nausea and gastrointestinal disturbances sometimes leading to
withdrawal of participants. Hypoglycaemic events are more fre-
quent in type 1 diabetes and occur about three hours following
meals. Risk of severe hypoglycaemia and hypoglycaemia- related
events (such as motor vehicle accidents) have determined the label
warning on this risk as well as the recommendation that pram-
lintide should be used under strict surveillance of a specialised,
experienced diabetes team, only in patients without known hypo-
glycaemia unawareness or gastroparesis or other gastric motility
disturbances. In addition, patients using pramlintide should be
carefully instructed on identifying and promptly treating hypo-
glycaemic episodes.
Why it is important to do this review
Pramlintide is a controversial and possibly under-explored drug in
diabetes mellitus. One health technology assessment (McQueen
2005) and two systematic reviews on pramlintide for diabetes mel-
litus were published (Nogid 2006; Singh-Franco 2007). Since the
date of their publication, randomised clinical trials exploring new
ways of use for pramlintide in diabetes mellitus have published
their results (Riddle 2007; Riddle 2009) and other post-marketing
randomised clinical trials are ongoing.
Our aim in doing this review is to identify and aggregate the good
quality evidence on pramlintide for diabetes mellitus. We will also
try to assess aspects like effects of pramlintide on health-related
quality of life, tolerance and acceptability of treatment and cost
related issues if feasible- as these aspects are important contribu-
tors to the strength of recommendation for use of pramlintide in
diabetes.
O B J E C T I V E S
To assess the effects of pramlintide for diabetes mellitus.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Randomised controlled clinical trials of any design.
Types of participants
Type 1 and type 2 diabetic patients will be included, irrespective
of age (over 18 as well as under 18 year old), gender or race.Type
2 diabetic patients both insulin-treated and non-insulin- treated,
regardless of background antidiabetic therapy will be included.
Diagnostic criteria
To be consistent with changes in classification and diagnostic cri-
teria of diabetes mellitus through the years, the diagnosis should
have been established using the standard criteria valid at the time
of the beginning of the trial (for example ADA 1997; ADA 1999;
WHO 1980; WHO 1985; WHO 1998). Ideally, diagnostic cri-
teria should have been described. If necessary, authors’ definition
of diabetes mellitus will be used. Diagnostic criteria will be even-
tually subjected to a sensitivity analysis.
Types of interventions
Intervention
• pramlintide alone or added to short or rapid acting insulin
(administered prior to meals by subcutaneous injection, in doses
ranging from 15 mcg per dose to 120 mcg per dose, with a
duration of intervention of at least 12 weeks).
Comparisons
• placebo;
• intensification of ’life-style’ interventions;
• continuous subcutaneous insulin infusion (CSII);
• intensification of insulin treatment;
• oral antidiabetic drugs (α-glucosidase inhibitors,
meglitinides, sulphonylurea, metformin);
• exenatide;
• no intervention.
Comparisons were selected based on the clinical rationale of tar-
geting postprandial hyperglycaemia.
Types of outcome measures
Primary outcomes
• overall glycaemic control as measured by glycosylated
haemoglobin A1c (HbA1c);
• hypoglycaemia; hypoglycaemic events will be graded as:
mild (symptoms easily controlled by individual),
moderate(normal activities interrupted but not requiring
assistance), severe (individual requiring assistance and associated
with blood glucose levels less than 50 mg/dL (4 mmol/L) or
prompt recovery after carbohydrate or glucagon administration)
(DCCT 1993). Classification of hypoglycaemic events as defined
by clinical trial protocols will also be considered and assessed;
• weight change as measured by body mass index or weight or
both.
Secondary outcomes
• mortality (death from any cause; diabetes related death -
death from myocardial infarction, stroke, peripheral vascular
disease, renal disease, hyper- or hypoglycaemia, sudden death);
• morbidity (morbidity from any cause; diabetes and
cardiovascular related morbidity - angina pectoris, myocardial
infarction, heart failure, renal failure, stroke, peripheral arterial
disease, neuropathy, retinopathy, erectile dysfunction,
amputation, blindness, vitreous haemorrhage, cataract);
• adverse events; adverse events will be considered as any
untoward medical occurrence not necessarily having a causal
relationship with the treatment. Serious adverse events will be
defined as any adverse event that results in death, is immediately
life-threatening, requires hospitalisation, or prolongation of
hospitalisation, results in persistent or significant disability or
incapacity, results in congenital anomaly or birth defect (as
defined by ICH 1997). Adverse events leading to patient
withdrawal will be assessed. Hypoglycaemic events or
hypoglycaemia-related adverse events will be considered ’primary
outcomes ’ and assessed separately;
• fasting and postprandial glucose;
• health-related quality of life (using a validated instrument);
• tolerance and acceptability of treatment;
• costs of treatment.
Covariates, effect modifiers and confounders
• HbA1c values at baseline (eg lower or higher than 8%);
• body mass index (BMI);
• age;
• diabetes onset, ie time from diagnosis;
• gender;
• race;
• co-morbidities;
• co-medication;
• duration of intervention.
Timing of outcome measurement
We will assess outcomes in the short term (equal or more than
12 weeks to less than 18 weeks), medium term (equal or more
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than 18 weeks to less than 52 weeks) and long term (equal or
more than 52 weeks). Data from long- term extension trials of
randomised controlled trials will be considered only if participants
are maintaining the same sequence allocation as in the initial-
feeder- trial.
Search methods for identification of studies
We will identify studies according to Cochrane Metabolic and
Endocrine Disorders Group methods used in reviews.
Electronic searches
We will use the following sources for the identification of trials:
• The Cochrane Library (latest issue);
• MEDLINE - (until recent);
• EMBASE - (until recent).
We will also search other databases:
• Current Controlled Trials - www.controlled-trials.com -
with links to other databases of ongoing trials;
• National Institutes of Health (NIH)/ National Library of
Medicine (NLM) - www.clinicaltrials.gov;
• Intenational Foundation of Pharmaceutical Manufacturers
& Associates (IFPMA) - www.ifpma.org;
• www.ClinicalStudyResults.org.
For detailed search strategies please see under Appendix 1.
Additional key words of relevance may be detected during any of
the electronic or other searches. If this is the case, electronic search
strategies will be modified to incorporate these terms. Studies pub-
lished in any language will be included.
Searching other resources
We will thoroughly search the U.S. Food and Drug Administra-
tion (U.S. FDA) site for data on pre-approval trials. Documenta-
tion submitted for drug approval will be appraised, matched with
published reports, appraised for unpublished data. If needed, the
authors of the review will contact the FDA medical officer signing
the FDA medical review for clarification and details (U.S. FDA
2009).
In addition,we will search the American Diabetes Association
(ADA) site and meetings abstracts as well as the European Associa-
tion for the Study of Diabetes (EASD) site and meetings abstracts.
We will also search manufacturer ’s site and we will contact man-
ufacturer’s representatives responsible with sponsor-funded trials
conduct for potential unpublished or incompletely available in-
formation from published trials.
We will try to identify additional studies by searching the reference
lists of included trials and (systematic) reviews, meta-analyses and
health technology assessment reports noticed.
Data collection and analysis
Selection of studies
To determine the studies to be assessed further, two authors (D.B.,
C.L.) will independently scan the abstract, title or both of every
record retrieved. All potentially relevant articles will be investi-
gated as full text. We will consider potentially relevant articles in
a sensitive, over-inclusive manner at first stage.
We will classify as eligible if:
• studies are randomised controlled trials;
• pramlintide is the intervention being compared;
• studies include diabetic patients.
Studies will be rejected as ineligible if:
• they are not randomised controlled trials (for example
pooled post-hoc analysis of data from two or more trials);
• they include non-diabetic patients (for example obese non-
diabetic patients);
• they evaluate a co-intervention (for example pramlintide
plus metreleptin) or an intervention administered in another way
than specified (dose, route, frequency of administration);
• the follow up period is less than 12 weeks - the time needed
for HbA1c changes to become clinically relevant;
• none of the outcomes of interest is measured (for example
biological markers or pharmacokinetics of drug only).
Interrater agreement for study selection will be measured using
the kappa statistic (Cohen 1960). Differences will be marked and
if these studies are late on included, the influence of the primary
choice will be subjected to a sensitivity analysis. Where differences
in opinion exist, they will by resolved by a third party (C.D.). If
resolving disagreement is not possible, the article will be added
to those ’awaiting assessment’ and authors will be contacted for
clarification. An adapted PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) flow-chart of study selec-
tion will be attached (Liberati 2009).
Data extraction and management
For studies that fulfil inclusion criteria, two authors (D.B., C.L.)
will independently abstract relevant population and intervention
characteristics using standard data extraction templates (for details
see ’Characteristics of included studies’ and Table 1, Appendix 2,
Appendix 3, Appendix 4, Appendix 5) with any disagreements to
be resolved by discussion, or if required by a third party (C.D.).
Any relevant missing information on the trial will be sought from
the original author(s) of the article, if required. We will also iden-
tify duplicate publications of the same report as well as compan-
ion reports by searching the reference section of reports found,
searching potential other publications by the same authors and by
contacting authors of the primary report. Sources of data will be
specified, compared and collated in the extraction form.
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Assessment of risk of bias in included studies
Two authors (D.B., C.L.) will assess each trial independently. The
reference source of information will be considered the clinical trial
protocol. Ideally, clinical trial protocols should be publicly available.
If this is not the case we will contact the corresponding author
of the primary published report for details. Access to the original
clinical trial protocol will be documented in the review and any
discrepancies between the protocol and the published trial report
will be acknowledged.
Assessment of risk of bias will be made at outcome level across
every key- domain, within each included study and across studies
according to the Collaboration’s tool in assessing risk of bias.
We will assess risk of bias as follows:
Sequence generation
• adequate (low risk of bias) if generated by a computerised
system as a reference method - interactive voice randomisation or
interactive web randomisation system (IVRS or IWRS) - other
methods (coin toss, random number tables or throwing dice) are
also acceptable as alternative methods of sequence generation;
• inadequate (high risk of bias) if system involves names,
dates,or admittance numbers;
• uncertain if randomisation is stated in report and we can
not obtain enough details.
Allocation sequence concealment
• adequate (low risk of bias) if a remote computerised system
is used, interactive voice randomisation or interactive web
randomisation systems (IVRS or IWRS) will be the method of
reference;
• inadequate if allocation sequence is known by investigators
or study is quasi-randomised;
• uncertain if allocation concealment is stated but insufficient
data are available.
Blinding
Risk of bias due to blinding will be assessed in consideration to
the type of outcome (Day 2000).
• adequate (low risk of bias) - for subjective outcomes (such
as health-related quality of life or adverse events as nausea )
blinding of study participants and personnel as well as blinding
of outcome assessors (triple blinding) should be provided; for
major objective outcomes (such as death of any cause or severe
hypoglycaemia) outcome assessors blinding would be sufficient;
ascertainment that blinding could not be broken should be
stated;
• inadequate (high risk of bias) - if study participants,
personnel and outcome assessors or either of them were
unblinded to treatment and outcome may be influenced by non-
blinding; blinding could have been broken;
• uncertain if blinding or blinding method can not be
determined from available data.
Incomplete outcome data
• adequate (low-risk of bias) - if there are no missing outcome
data; if missing outcome data are unlikely related to the outcome
(for example censoring for survival data ); if the proportions of
missing outcome data compared with the observed event risk are
unlikely to impact on the intervention effect estimate (for
dichotomous data ); if the plausible effect size among missing
outcomes is not enough to have a clinically relevant impact on
the observed effect size (for continuous outcome data ); if missing
outcome data are balanced in numbers across intervention
groups with similar reasons for missing data across groups and
missing data are dealt with using appropriate methods;
• inadequate (high risk of bias) - if reasons for missing
outcome data are likely related to true outcomes with imbalances
either in numbers between treatment groups or in reasons for
missing data across intervention groups; if the proportion of
missing outcome data compared to the observed event risk is
enough to induce bias in effect estimates (for dichotomous data);
if the plausible effect size among missing outcomes is enough to
induce clinically relevant bias in observed effect sizes (for
continuous outcome data); if reasons for withdrawal are not
explained; if only ’as treated’ analysis was performed; if
potentially inappropriate methods were used for dealing with
missing data;
• uncertain if data on attrition and exclusion or both were not
clear or sufficient and reasons for withdrawal were incomplete.
Selective reporting of outcomes
To assess selective reporting of outcomes, authors of the review
will compare the ’methods’ section and ’results’ section of each
trial report - in primary as well as companion reports identified. If
possible, we will also compare outcomes data retrieved from pub-
lished reports with outcomes stated in the clinical trial protocols
(Chan 2004).
• adequate (low risk of bias) - if all outcomes stated in the
’methods’ section of the published report of the trial overlap with
the stated outcomes in the clinical trial protocol, are analysed
and presented in the ’results’ section of the report as stated in the
protocol;
• inadequate (high risk of bias) - if one ore more pre-specified
outcomes are not reported, or analysed and reported in a
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different manner than stated in the trial protocol; if one or more
primary outcomes are reported that were not pre-specified
(unless there is a justified reason such as an unexpected adverse
event); if reporting of a major outcome is incomplete and can
not be entered in a meta-analysis; if only a statement of ’non-
significant’ will be found in ’results’ section; if outcomes are
changed during the trial;
• uncertain if insufficient information can be obtained on
outcomes.
Other bias
Early stopping for benefit will be considered ’high risk of bias’
(Montori 2008a).
Baseline characteristics imbalance in the treatment groups if ex-
treme will be considered ’high risk of bias’.
Sponsor bias will be considered if insufficient data are publicly
available and access to other important information is denied by
sponsor. Attempts to contact sponsor representatives responsible
for the trial conduct will be documented as well as the information
provided. Sponsor-bias is a complex potential source of bias that
may pervade research from early stages - for example by selecting
comparisons that favour intervention (Bekelman 2003; Lexchin
2003;Montori 2008b) - to reporting anddisseminationof research
results (Gøtzsche 2006; Graf 2009; Lexchin 2003) and may be
present even if trials are of good methodological quality (Lexchin
2003).The potential influence of sponsor-bias on the overall effect
of the intervention will be subject to sensitivity analysis .
Possible disagreement will be resolved by consensus, or with con-
sultation of a third party (C.D.) in case of disagreement. Interrater
agreement for key bias indicators (eg allocation concealment, in-
complete outcome data) will be calculated using the kappa statistic
(Cohen 1960).
Measures of treatment effect
Dichotomous data
Dichotomous data (for example number of participants achieving
an HbA1c less than 7%, number of participants experiencing a
hypoglycaemic event) will be expressed as odds ratios (OR) and
relative risk (RR) with 95% confidence intervals (CI).
Continous data
Continuous data (for example change of HbA1c from baseline,
change in weight, decrease of postprandial glycaemic values) will
be summarised as weighted mean difference (WMD) with 95%
CI. For studies addressing the same outcome but using different
outcome measures we will use the standardized mean difference
(SMD).
Time to event data
Time-to-event outcomes (for example time until development of
diabetic retinopathy) will be expressed as hazard ratios (HR) with
95% CI.
Unit of analysis issues
If RCTs of different design other than parallel arms design will
be found (for example cross-over, factorial or cluster randomised
trials) we will seek assistance from an experienced statistician in
appraising the statistical analysis of the trial or other related issues.
Dealing with missing data
Wewill obtain relevantmissing data by collating information from
different sources (for example primary and any companion pub-
lication of the trial) and, eventually, from authors of the reports,
if feasible. We will carefully perform evaluation of important nu-
merical data such as screened, randomised patients as well as inten-
tion-to-treat (ITT) and per-protocol (PP) population. We will in-
vestigate attrition rates, for example drop-outs, losses to follow-up
and withdrawals. Issues of missing data and techniques to handle
these (for example, last-observation-carried-forward (LOCF)) will
be critically appraised.We will also seek a statistician’s assistance in
appraising the method of handling missing data in included trials.
Assessment of heterogeneity
We will identify heterogeneity by visual inspection of the forest
plots, by using a standard Chi2 test and a significance level of
α = 0.1. In view of the low power of such tests heterogeneity
will be specifically examined with the I2 statistic (Higgins 2002),
where I2 values of 50% and more indicate a substantial level of
heterogeneity (Higgins 2003). When heterogeneity is found, we
will attempt to determine potential reasons for it by examining
individual study and subgroup characteristics.
In the event of substantial clinical or methodological or statistical
heterogeneity, studies will not be combined by means of meta-
analysis.
Assessment of reporting biases
We will use funnel plots to assess for the potential existence of
small study bias. There are a number of explanations for the asym-
metry of a funnel plot (Sterne 2001). Therefore, we will carefully
interpret results (Lau 2006).
Data synthesis
Data will be summarised statistically if they are available, suffi-
ciently similar and of sufficient quality. We will perform statisti-
cal analysis according to the statistical guidelines referenced in the
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newest version of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2009).
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analyses if one of the primary out-
come parameters demonstrates statistically significant differences
between intervention groups. In any other case subgroup analyses
will be clearly marked as a hypothesis generating exercise.
The following subgroup analyses are planned:
• type 1 and type 2 diabetes;
• age under 18 or over 18 years;
• baseline HbA1c below 8% or above 8%.
Subgroup analyses will be performed, if feasible, to identify sub-
groups that may carry a higher risk from treatment and subgroups
that may benefit more from treatment. The methodology of sub-
group analyses in both randomised clinical trials and systematic re-
views of interventions is still uncertain and currently under inves-
tigation (Sun 2009). We will interpret cautiously findings of sub-
group analysis (Fletcher 2007) and, if necessary, will seek method-
ological advice.
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influ-
ence of the following factors on effect size:
• repeating the analysis excluding unpublished studies;
• repeating the analysis taking account of risk of bias, as
specified above;
• repeating the analysis excluding any very long or large
studies to establish how much they dominate the results;
• repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), country.
We will also test the robustness of the results by repeating the anal-
ysis using different measures of effects size (relative risk, odds ratio
etc.) and different statistical models (fixed-model and random-ef-
fects model).
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A D D I T I O N A L T A B L E S
Table 1. Overview of study populations
Study ID Interven-
tion(s) &
control(s)
[n] screened [n]
randomised
[n] safety [n] ITT [n] finish-
ing study
[%] of ran-
domised
partici-
pants
finishing
study
Comments
ID1 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
ID2 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
ID3 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
ID3 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
ID4 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
ID5 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
ID6 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
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Table 1. Overview of study populations (Continued)
ID7 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
ID8 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
ID9 I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
Total I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
C: control; I: intervention; ITT: intention-to-treat
A P P E N D I C E S
Appendix 1. Search strategies
Search terms
Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp =
exploded MeSH; the dollar sign ($) or asterisk (*) stand for any character(s); the question mark (?) = to substitute for one or no
characters; ab = abstract; adj = adjacent; ot = original title; pt = publication type; rn = Registry number or Enzyme Commission
number; sh = MeSH; ti = title; tw = text word
The Cochrane Library , Issue 3.2009
#1 MeSH descriptor Diabetes Mellitus explode all trees
#2 (diabet*)
#3 (IDDM or NIDDM or MODY or T1DM or T2DM)
#4 (non insulin* depend* or noninsulin* depend* or non insulin?depend* or non insulin?depend*)
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(Continued)
#5 (insulin* depend* or insulin?depend*)
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor Diabetes Insipidus explode all trees
#8 (diabet* insipidus)
#9 (#7 OR #8)
#10 (#6 AND NOT #9)
#11 (pramlintid* or symlin*)
#12 (amylin* near6 analog*)
#13 (amylin mimetic* or amylinmimetic*)
#14 (#11 OR #12 OR #13)
#15 (#10 AND #14)
Medline (1950 to July Week 5 2009)
1. (pramlintid* or symlin*).tw,ot.
2. 151126-32-8.rn.
3. (amylin* adj6 analo?g*).tw,ot.
4. amylin?mimetic*.tw,ot.
5. or/1-4
6. exp Diabetes Mellitus/
7. diabet*.tw,ot.
8. (IDDM or NIDDM or MODY or T1DM or T2DM).tw,ot.
9. (non insulin* depend* or noninsulin* depend* or non insulin?depend* or noninsulin?depend*).tw,ot.
10. (insulin* depend* or insulin?depend*).tw,ot.
11. exp Diabetes Insipidus/
12. diabet* insipidus.tw,ot.
13. or/6-10
14. 11 or 12
15. 13 not 14
16. 5 and 15
17. randomized controlled trial.pt.
18. controlled clinical trial.pt.
19. randomi?ed.ab.
20. placebo.ab.
21. drug therapy.fs.
22. randomly.ab.
23. trial.ab.
24. groups.ab.
25. or/17-24
26. Meta-analysis.pt.
27. exp Review/
28. exp Technology Assessment, Biomedical/
29. exp Meta-analysis as topic/
30. hta.tw,ot.
31. (health technology adj6 assessment*).tw,ot.
32. (meta analy* or metaanaly* or meta?analy*).tw,ot.
33. ((review* or search*) adj10 (literature* or medical database* or medline or pubmed or embase or cochrane or cinahl or psycinfo
or psyclit or healthstar or biosis or current content* or systemat*)).tw,ot.
34. or/26-33
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(Continued)
35. (comment or editorial or historical-article).pt.
36. 34 not 35
37. 25 or 36
38. 16 and 37
39. (animals not (animals and humans)).tw,ot.
40. 38 not 39
EMBASE (EMBASE <1980 to 2009 August 5)
1. exp pramlintide/
2. (pramlintid* or symlin*).tw,ot.
3. (amylin* adj6 analog*).tw,ot.
4. amylin?mimetic*.tw,ot.
5. or/1-4
6. exp Diabetes Mellitus/
7. diabet*.tw,ot.
8. (non insulin* depend* or noninsulin* depend* or non insulin?depend* or noninsulin?depend*).tw,ot.
9. (insulin* depend* or insulin?depend*).tw,ot.
10. (IDDM or NIDDM or MODY or T1DM or T2DM or T1d or T2D).tw,ot.
11. or/6-10
12. exp Diabetes Insipidus/
13. diabet* insipidus.tw,ot.
14. 12 or 13
15. 11 not 14
16. 5 and 15
17. exp Randomized Controlled Trial/
18. exp Controlled Clinical Trial/
19. exp Clinical Trial/
20. exp Comparative Study/
21. exp Drug comparison/
22. exp Randomization/
23. exp Crossover procedure/
24. exp Double blind procedure/
25. exp Single blind procedure/
26. exp Placebo/
27. exp Prospective Study/
28. ((clinical or control* or comparativ* or placebo* or prospectiv* or randomi?ed) adj3 (trial* or stud*)).ab,ti.
29. (random* adj6 (allocat* or assign* or basis or order*)).ab,ti.
30. ((singl* or doubl* or trebl* or tripl*) adj6 (blind* or mask*)).ab,ti.
31. (cross over or crossover).ab,ti.
32. or/17-31
33. exp meta analysis/
34. (metaanaly* or meta analy* or meta?analy*).ab,ti,ot.
35. ((review* or search*) adj10 (literature* or medical database* or medline or pubmed or embase or cochrane or cinahl or psycinfo
or psyclit or healthstar or biosis or current content* or systematic*)).ab,ti,ot.
36. exp Literature/
37. exp Biomedical Technology Assessment/
38. hta.tw,ot.
39. (health technology adj6 assessment*).tw,ot.
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(Continued)
40. or/33-39
41. (comment or editorial or historical-article).pt.
42. 40 not 41
43. 32 or 42
44. 16 and 43
45. limit 44 to human
Appendix 2. Description of interventions
Charac-
teristic
study ID1 study ID2 study ID3 study ID4 study ID5 study ID6 study ID7 study ID8 study ID9
Interven-
tion(s)
[route, fre-
quency, to-
tal dose/
day]
I1:
I2:
I1:
I2:
I1:
I2:
I1:
I2:
I1:
I2:
I1:
I2:
I1:
I2:
I1:
I2:
I1:
I2:
Control(s)
[route, fre-
quency, to-
tal dose/
day]
C1:
C2:
C1:
C2:
C1:
C2:
C1:
C2:
C1:
C2:
C1:
C2:
C1:
C2:
C1:
C2:
C1:
C2:
Footnotes
C: control; I: intervention
Appendix 3. Baseline characteristics
Charac-
teristic
study ID1 study ID2 study ID3 study ID4 study ID5 study ID6 study ID7 study ID8 study ID9
Interven-
tion(s) &
control(s)
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Participat-
ing popu-
lation
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(Continued)
Sex
[female% /
male%]
Age [mean
years (SD)]
Dura-
tion of dis-
ease [mean
years (SD)]
HbA1c
[mean %
(SD)]
BMI
[mean kg/
m2 (SD)]
Ethnic
groups [%]
Dura-
tion of in-
tervention
Dura-
tion of fol-
low up
Footnotes
BMI: body mass index; C: control; HbA1c: glycosylated haemoglobin A1c; I: intervention
Appendix 4. Matrix of study endpoints
Charac-
teristic
study ID1 study ID2 study ID3 study ID4 study ID5 study ID6 study ID7 study ID8 study ID9
Interven-
tion(s) &
control(s)
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
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(Continued)
Primary
1 endpoint
(s)
Secondary
2 endpoint
(s)
Other
3 endpoint
(s)
Footnotes
1,2 as stated in the publication; 3 not stated as primary or secondary endpoint(s) in the publication
C: control; I: intervention
Appendix 5. Adverse events
Charac-
teristic
study ID1 study ID2 study ID3 study ID4 study ID5 study ID6 study ID7 study ID8 study ID9
Interven-
tion(s) &
control(s)
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
I1:
I2:
C1:
C2:
Deceased
partici-
pants [n]
I1: n / N
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
Adverse
events [n /
%]
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
Serious ad-
verse
events [n /
%]
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
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Drop-
outs due to
adverse
events [n /
%]
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
Hospital-
isation [n /
%]
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
Out-pa-
tient treat-
ment [n /
%]
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
Hypogly-
caemic
episodes [n
/ %]
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
Se-
vere hypo-
glycaemic
episodes [n
/ %]
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
Defini-
tion of se-
vere / seri-
ous hypo-
glycaemia
Noctur-
nal hypo-
glycaemic
episodes [n
/ %]
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
Symptoms
[n / %]
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
I1:
I2:
C1:
C2:
Total:
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Footnotes
C: control; I: intervention
H I S T O R Y
Protocol first published: Issue 2, 2010
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analysis, final review development.
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development .
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